Venmax Drugs & Pharmaceuticals quarterly results and financials

Venmax Drugs & Pharmaceuticals (BSE 531015)₹14.65+5.40%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Mar 2026 quarter (standalone), Venmax Drugs & Pharmaceuticals reported sales of ₹3.93 Cr, up 1,128.1% from Mar 2025, and net profit of ₹0.10 Cr, down 87.0% year on year. For the year to Mar 2026, sales were ₹8.01 Cr and net profit ₹0.24 Cr.

Sales (Mar 2026): ₹3.93 Cr
Net profit (Mar 2026): ₹0.10 Cr
Sales (FY Mar 2026): ₹8.01 Cr
Net profit (FY Mar 2026): ₹0.24 Cr
EPS (Mar 2026): ₹0.10
Borrowings (Mar 2026): ₹0.33 Cr

Company filings, standalone accounts; latest reported quarter Mar 2026

Venmax Drugs & Pharmaceuticals quarterly results

₹ crore unless stated; each column is a quarter.

Venmax Drugs & Pharmaceuticals Quarterly results
	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	0.00	0.00	0.00	0.00	0.09	0.16	0.19	0.32	1.20	1.31	1.54	3.93
Expenses	0.02	0.02	0.00	0.03	0.11	0.46	0.68	0.56	1.16	1.26	1.57	3.91
Operating Profit	−0.04	−0.04	−0.02	−0.05	−0.03	−0.31	−0.50	−0.25	0.05	0.06	−0.04	0.03
OPM %	—	—	—	—	−20.0%	−176.4%	−245.0%	−72.7%	3.3%	3.8%	−1.9%	0.5%
Other Income	0.04	0.00	0.04	0.09	0.02	0.00	0.00	1.01	0.00	0.00	0.06	0.08
Interest	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	0.01	−0.02	0.05	0.05	0.00	−0.29	−0.48	0.77	0.03	0.04	0.03	0.10
Tax %	0.0%	0.0%	25.0%	16.6%	0.0%	0.0%	0.0%	0.0%	0.0%	39.9%	25.0%	0.0%
Net Profit	0.01	−0.02	0.02	0.04	0.00	−0.29	−0.49	0.77	0.03	0.01	0.02	0.10
EPS (Rs)	0.05	−0.07	0.07	0.11	0.03	−0.58	−0.96	1.50	0.09	0.03	0.05	0.10

Venmax Drugs & Pharmaceuticals profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Venmax Drugs & Pharmaceuticals Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	1.92	0.25	0.00	0.14	0.46	0.16	0.00	0.00	0.00	0.80	8.01	7.98
Expenses	2.06	0.87	0.22	0.37	0.71	0.49	0.11	0.18	0.10	1.73	7.87	7.90
Operating Profit	−0.15	−0.63	−0.24	−0.24	−0.26	−0.34	−0.13	−0.20	−0.12	−0.94	0.13	0.10
OPM %	−7.2%	−238.4%	—	−153.3%	−53.2%	−194.1%	—	—	—	−114.7%	1.5%	1.3%
Other Income	0.00	−0.71	0.00	0.00	0.00	0.17	1.97	0.41	0.19	0.91	0.15	0.14
Interest	0.00	0.00	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Profit before tax	−0.13	−1.33	−0.23	−0.23	−0.25	−0.15	1.84	0.21	0.07	−0.01	0.27	0.20
Tax %	0.0%	0.0%	0.0%	0.0%	3.8%	0.0%	0.0%	0.0%	25.0%	0.0%	10.7%	—
Exceptional items	0.00	−1.01	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—
Net Profit	−0.13	−1.33	−0.23	−0.23	−0.26	−0.15	1.84	0.22	0.05	0.00	0.24	0.16
EPS (Rs)	−0.28	−2.57	−0.47	−0.47	−0.53	−0.32	3.54	0.43	0.12	−0.03	0.23	0.27
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	—

Venmax Drugs & Pharmaceuticals balance sheet

₹ crore, at each year end.

Venmax Drugs & Pharmaceuticals Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	5.23	5.23	5.23	5.22	5.23	5.23	5.23	5.23	5.23	5.23	5.23	11.53
Reserves	−4.91	−5.05	−7.12	−7.36	−7.60	−7.87	−8.04	−6.19	−5.96	−5.90	−0.84	2.53
Borrowings	1.51	1.73	1.86	2.05	2.25	2.53	2.34	0.36	0.36	0.36	0.06	0.33
Other Liabilities	1.86	0.67	0.16	0.15	0.43	0.55	0.75	0.79	0.56	0.37	0.70	1.75
Total Liabilities	3.69	2.58	0.13	0.06	0.31	0.44	0.28	0.19	0.19	0.06	5.15	16.14
Fixed Assets	0.00	0.00	0.00	0.00	0.10	0.09	0.08	0.07	0.06	0.06	0.03	0.03
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Assets	3.67	2.58	0.13	0.06	0.21	0.35	0.20	0.12	0.13	0.00	5.12	16.11
Inventories	1.46	0.00	0.00	0.00	0.10	0.21	0.00	0.00	0.00	0.00	0.05	0.99
Trade receivables	0.13	0.67	0.00	0.00	0.00	0.05	0.05	0.03	0.05	0.00	0.96	1.44
Cash & equivalents	0.00	0.04	0.00	0.00	0.00	0.00	0.09	0.00	0.00	0.00	2.49	1.23
Total Assets	3.69	2.58	0.13	0.06	0.31	0.44	0.28	0.19	0.19	0.06	5.15	16.14

Venmax Drugs & Pharmaceuticals cash flow

₹ crore, for each year.

Venmax Drugs & Pharmaceuticals Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2025	Mar 2026
Cash from operating activity	−0.11	−0.20	−1.07	−0.27	−0.06	−0.29	0.27	1.92	−2.30	−11.04
Cash from investing activity	0.00	0.00	0.02	0.00	−0.12	0.00	0.00	0.00	0.00	0.00
Cash from financing activity	0.11	0.23	1.03	0.27	0.17	0.29	−0.18	−1.99	4.78	9.75
Net cash flow	0.00	0.04	−0.04	0.00	0.00	0.00	0.08	−0.08	2.49	−1.27
Capex	0.00	0.00	0.00	0.00	0.13	0.00	0.00	0.00	0.00	0.00
Free cash flow	−0.11	−0.20	−1.06	−0.27	−0.18	−0.29	0.27	1.92	−2.30	−11.03
CFO / OP %	127.1%	136.0%	171.0%	113.0%	22.1%	112.0%	−79.0%	−1,592.0%	246.0%	−9,142.0%

Venmax Drugs & Pharmaceuticals ratios

Working-capital days and returns, by year.

Venmax Drugs & Pharmaceuticals Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2019	Mar 2020	Mar 2021	Mar 2025	Mar 2026
Debtor days	21	129	0	0	31	86	428	65
Inventory days	224	0	0	445	250	0	27	49
Days payable	252	—	—	1,257	456	—	291	84
Cash conversion cycle	−6	128	0	−812	−175	85	164	30
Working capital days	−3	6	−2,723	−5,986	−2,112	−6,334	852	588
ROCE %	−6.0%	−7.4%	−52.6%	—	—	—	5.3%	3.0%

Venmax Drugs & Pharmaceuticals: frequently asked questions

What are the latest quarterly results of Venmax Drugs & Pharmaceuticals?

For the Mar 2026 quarter, Venmax Drugs & Pharmaceuticals reported sales of ₹3.93 Cr, up 1,128.1% year on year and net profit of ₹0.10 Cr, down 87.0% year on year. The operating margin was 0.5%.

What is the annual revenue of Venmax Drugs & Pharmaceuticals?

Venmax Drugs & Pharmaceuticals' sales for the year to Mar 2026 were ₹8.01 Cr; over the last twelve months they were ₹7.98 Cr.

What is the net profit of Venmax Drugs & Pharmaceuticals?

Net profit for the year to Mar 2026 was ₹0.24 Cr, and ₹0.16 Cr over the last twelve months. Earnings per share over the same trailing period were ₹0.27.

How much debt does Venmax Drugs & Pharmaceuticals have?

Venmax Drugs & Pharmaceuticals reported borrowings of ₹0.33 Cr at Mar 2026, against cash and equivalents of ₹1.23 Cr.

What is the free cash flow of Venmax Drugs & Pharmaceuticals?

Cash from operations was −₹11.04 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹11.03 Cr.

Loading…